Search Results

The phase III PRIMA/ENGOT-OV26/GOG-3012 trial evaluated the efficacy of niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who responded to platinum-based chemotherapy. In this final analysis, no significant difference in overall survival was observed between niraparib and placebo in the overall or homologous recombination-deficient (HRd) populations. However, long-term progression-free survival and […]

The phase III CAPItello-290 trial assessed the combination of capivasertib (C) with paclitaxel (P) as a first-line treatment for metastatic triple-negative breast cancer compared to paclitaxel plus placebo. A total of 812 patients were enrolled, with 30.7% showing PIK3CA/AKT1/PTEN alterations. While progression-free survival slightly favoured the C+P combination, the primary endpoint of overall survival was […]

he DESTINY-Breast06 (DB-06) trial explored the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with hormone receptor-positive (HR+), HER2-low or HER2-ultralow metastatic breast cancer (mBC). Patients were screened for HER2 status and randomized to receive either T-DXd or treatment of the physician's choice (TPC). Results showed that T-DXd significantly improved progression-free survival (PFS) compared to TPC, across various HER2 classifications.

The NIAGARA trial evaluated the combination of durvalumab (D) with neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and adjuvant durvalumab in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A total of 1063 patients were randomized to either receive durvalumab + NAC + RC followed by adjuvant durvalumab or NAC + RC alone. The study […]

The phase II RELATIVITY-104 trial assessed the combination of nivolumab (NIVO) and relatlimab (RELA), a LAG-3-blocking antibody, alongside chemotherapy (PDCT) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). In this randomized trial, patients receiving NIVO + RELA + PDCT demonstrated a higher overall response rate (ORR) (51.3%) compared to NIVO + PDCT […]

The ATHENA trial evaluated the effectiveness of rucaparib (RUCA) monotherapy (MONO) and rucaparib combined with nivolumab (NIVO) (COMBO) in patients with advanced high-grade ovarian cancer (AHGOC). In the MONO arm, rucaparib showed sustained progression-free survival (PFS) of 20.2 months after first-line treatment. However, the COMBO arm did not improve PFS, with median PFS being shorter […]

The annual European Society of Gynaecological Oncology (ESGO) Congress, held from 7–10 March 2024, in Barcelona, Spain, celebrated its 25th anniversary this year. This year’s congress brought together over 2,500 participants from all over the world, and featured groundbreaking research, clinical advancements and professional development opportunities.

Dr Ken Kato is a medical oncologist and the Chief of the Department of Head and Neck, Esophageal Medical Oncology, and Gastrointestinal Medical Oncology at the National Cancer Center Hospital, Tokyo, Japan (2020-2024). Additionally, he serves as the Chief of the Biobank Translational Research Support Section within the Clinical Research Coordinating Section at the Clinical […]